Biotechnology & Medical Research

Page 1

DiaMedica Inc announces restructuring

Tuesday, 9 Dec 2014 06:30pm EST

DiaMedica Inc:announces restructuring aimed at preserving cash, reducing operating costs and re-positioning the company going forward.The company's restructuring includes a number of staff layoffs, including John Savage as Chief Financial Officer.DiaMedica plans to continue working with Savage on a part-time, consultancy basis.

EPS Corporation to transfer business to subsidiary

Wednesday, 19 Nov 2014 02:00am EST

EPS Corporation:To transfer clinical research organization business to a wholly owned subsidiary, which was set up on July 1 in Tokyo to prepare for restructuring of the company.Effective Jan. 2015.Subsidiary to issue 1,000 common shares to EPS Corporation.

ChronTech Pharma proposes sale of biotech operations and change of business to real estate

Tuesday, 18 Nov 2014 08:49am EST

ChronTech Pharma AB:Proposes change of business to real estate.Proposes transfer of wholly-owned subsidiary Tripep AB to AB Kulissen, a company owned by family Smith, for a purchase price of 4 million crowns.Says Tripep AB has acquired Chrontech Pharma's entire biotechnology business.Says proposes a new share issue of a maximum of 800 million shares at a price of - after reduction of the quota value - 0.01 Swedish crowns per share.Says issue is directed to the company's main shareholder, Margareta Smith.Says the company has a debt of about 8 million crowns to Margareta Smith.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.